This study is in progress, not accepting new patients
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
a study on Lung Cancer Non-Small Cell Lung Cancer Immunotherapy
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Dates
- study startedestimated completion
- Principal Investigator
- Matthew Gubens
Description
Summary
Official Title
Keywords
Eligibility
Lead Scientist at UCSF
- Matthew Gubens
Associate Professor, Medicine. Authored (or co-authored) 39 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme Corp.
- ID
- NCT02039674
- Phase
- Phase 1/2
- Study Type
- Interventional
- Last Updated